Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Related Questions
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
What are your top takeaways in thoracic cancers from ESMO 2025?
Would you treat a patient with an N2 ipsilateral recurrence following re-resection of bronchial stump recurrence?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
Would the presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
